BIOLIFE4D is committed to perfecting the technology to make viable organ replacement a safe, accessible and affordable reality. With BIOLIFE4D, a patient-specific, fully functioning heart would be created through 3D bioprinting and the patient’s own cells, eliminating the challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods.
BUFFALO GROVE, Ill., Dec. 31, 2021 (GLOBE NEWSWIRE) — BIOLIFE4D Corporation today announced that it intends to submit a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission in early 2022 for a proposed underwritten public offering of its common stock. The number of shares of common stock to be sold…